Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Cerus Corporation

Market Cap 519M 448M 413M 387M 725M 49.33B 736M 4.88B 1.9B 24.01B 1.95B 1.91B 83.13B P/E Ratio 2026 *
-77.7x
P/E Ratio 2027 * -778x
Enterprise Value 519M 448M 413M 387M 725M 49.33B 736M 4.88B 1.9B 24.01B 1.95B 1.91B 83.13B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 2x
Free-Float
96.59%
Yield 2026 *
-
Yield 2027 * -
1 day-0.19%
1 week-4.61%
Current month-14.97%
1 month+1.37%
3 months+52.06%
6 months+18.58%
Current year+25.49%
1 week 2.46
Extreme 2.46
2.81
1 month 2.33
Extreme 2.33
3.13
Current year 1.62
Extreme 1.62
3.15
1 year 1.15
Extreme 1.15
3.15
3 years 1.12
Extreme 1.12
3.15
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 59 21/04/2011
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 20/06/2025
Director/Board Member 72 24/03/2014
Director/Board Member 66 09/10/2018
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Director

60,000 0.0299%
06-02Free

Director

60,000 0.0299%
06-02Free

Director

60,000 0.0299%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-4.61%+88.69%+1.77% 519M
+2.75%+2.50%-17.66%+11.93% 117B
-0.31%-1.22%+2.12%-4.39% 12.86B
+2.05%+1.45%+29.93%+89.47% 7.29B
+1.87%-3.51%-46.74%-69.06% 4.12B
+2.06%+5.59%+11.04%+33.01% 2.49B
+5.46%+10.30%-16.96%-14.78% 1.7B
+1.67%-6.39%+3.63%-11.43% 1.63B
-8.89%-8.45%+165.17%+112.14% 1.49B
Average +0.74%+0.15%+24.36%+16.52% 16.59B
Weighted average by Cap. +2.36%+1.36%-11.52%+12.83%

Financials

2026 *2027 *
Net sales 238M 206M 190M 177M 332M 22.63B 338M 2.24B 872M 11.02B 894M 875M 38.14B 260M 224M 207M 194M 363M 24.7B 368M 2.44B 952M 12.02B 975M 954M 41.62B
Net income -6.24M -5.39M -4.96M -4.65M -8.71M -593M -8.84M -58.62M -22.86M -289M -23.41M -22.91M -999M -479K -414K -381K -357K -669K -45.56M -680K -4.5M -1.76M -22.18M -1.8M -1.76M -76.78M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
12/06/26 2.585 $ -0.19% 1,039,881
11/06/26 2.590 $ +1.17% 3,859,805
10/06/26 2.560 $ -0.78% 1,840,934
09/06/26 2.580 $ -0.77% 2,240,904
08/06/26 2.600 $ -4.06% 1,672,954
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.590USD
Average target price
4.667USD
Spread / Average Target
+80.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!